High-density lipoprotein, beta cells, and diabeteś

Cardiovascular Research

Volumn 103, Issue 3, 2014, Pages 384-394

  Von Eckardstein, Arnold ^a   Widmann, Christian ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Apoptosis; Diabetes; ER stress; HDLs; Pancreatic beta cells; Protective signals; Signalling

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MICRORNA; MICRORNA 33; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; THAPSIGARGIN; TRIACYLGLYCEROL; TUNICAMYCIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; APOPTOSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; INS 1 CELL LINE; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CELL; MIN6 CELL LINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERALL SURVIVAL; PANCREAS ISLET BETA CELL; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANIMAL; BLOOD; DIABETES MELLITUS; ENDOPLASMIC RETICULUM; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; PROTECTION; RISK FACTOR;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CELL SURVIVAL; CHOLESTEROL, HDL; DIABETES MELLITUS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PROTECTIVE FACTORS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84905584764     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu143     Document Type: Review

References (120)

1. Inzucchi SE. Clinical practice. Diagnosis of diabetes. N Engl J Med 2012;367:542-550
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin AA, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, De Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De LD, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, ODonnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA III, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128
3. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 2010;375:735-742
4. Preiss D, Seshasai SR,Welsh P, Murphy SA, Ho JE,Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, De Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 2011;305: 2556-2564
5. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61: 148-152
6. KaradagMK, Akbulut M.LowHDLlevels as the mostcommon metabolic syndromerisk factor in heart failure. Int Heart J 2009;50:571-580
7. Rahilly-Tierney CR, Spiro A III, Vokonas P, Gaziano JM. Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study). Am J Cardiol 2011;107:1173-1177
8. Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS. Low levels of highdensity lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J AmColl Cardiol 2013;62:1826-1833
9. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310
10. von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-Aged Caucasian male participants of the PROCAM study: Implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 2000;85:3101-3108
11. Montonen J, Drogan D, Joost HG, Boeing H, Fritsche A, Schleicher E, Schulze MB, Pischon T. Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur J Epidemiol 2011;26:29-38
12. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, DAgostino RB Sr. Prediction of incident diabetes mellitus in middle-Aged adults: The Framingham Offspring Study. Arch Intern Med 2007;167:1068-1074
13. Abbasi A, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL, Stolk RP, Navis G, Bakker SJ, Dullaart RP. Role ofHDLcholesterol and estimates ofHDLparticle composition in future development of type 2 diabetes in the general population: The PREVEND study. J Clin Endocrinol Metab 2013;98:E1352-E1359
14. Hersberger M, von Eckardstein A. Low high-density lipoprotein cholesterol: Physiological background, clinical importance and drug treatment. Drugs 2003;63: 1907-1945
15. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
16. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, LaRosa JC,Welch KM, AmarencoP, DeMicco DA, TonkinAM, Sullivan DR, Kirby A, ColhounHM,Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-Analysis. Circulation 2013;128:1504-1512
17. Li N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH. Are hypertriglyceridemia and lowHDL causal factors in the development of insulin resistance?. Atherosclerosis 2014;233:130-138
18. Aranda JF, Madrigal-Matute J, Rotllan N, Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med 2013;64:31-39
19. Rayner KJ, Moore KJ. MicroRNA control of high-density lipoprotein metabolism and function. Circ Res 2014;114:183-192
20. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase Cd pathway. J Lipid Res 2007;48:1062-1068
21. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22:26-32
22. DrewBG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role ofHDLin glucose metabolism. Nat Rev Endocrinol 2012;8:237-245
23. De HaanW, Bhattacharjee A, Ruddle P, Kang MH, Hayden MR. ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. J Lipid Res 2014;55:516-523
24. Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, Omer M, Subramanian S,Wang S,DenHartigh LJ,WeiH, Kim EJ, Kim J, OBrien KD, Chait A. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 2013;112:1345-1354
25. Carey AL, Siebel AL, Reddy-Luthmoodoo M, Natoli AK, DSouza W, Meikle PJ, Sviridov D, Drew BG, Kingwell BA. Skeletal muscle insulin resistance associated with cholesterol-induced activation of macrophages is prevented by high density lipoprotein. PLoS ONE 2013;8:e56601
26. Dalla-Riva J, Stenkula KG, Petrlova J, Lagerstedt JO. Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle. J Lipid Res 2013;54:1275-1282
27. Lehti M, Donelan E, Abplanalp W, Al-Massadi O, Habegger KM, Weber J, Ress C, Mansfeld J, Somvanshi S, Trivedi C, Keuper M, Ograjsek T, Striese C, Cucuruz S, Pfluger PT, Krishna R, Gordon SM, Silva RA, Luquet S, Castel J, Martinez S, DAlessio D, Davidson WS, Hofmann SM. High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 2013;128: 2364-2371
28. Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: Potential for clinical management of vascular disease. Circulation 2013;128:1112-1121
29. AnnemaW, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013;77:2432-2448
30. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-433
31. Regazzi R, Widmann C. Genetics and molecular biology: MiRNAs take the HDL ride. Curr Opin Lipidol 2012;23:165-166
32. Frias MA, JamesRW, Gerber-Wicht C, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate. Cardiovasc Res 2009;82:313-323
33. Nofer JR, van Der GM, Tolle M, Wolinska I, von Wnuck LK, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B.HDLinduces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-581
34. Chapman MJ. Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol 1986;128:70-143
35. NanjeeMN, Cooke CJ,Wong JS,Hamilton RL, Olszewski WL, Miller NE. Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: Quantification of cholesterol uptake by HDL in tissue fluids. J Lipid Res 2001;42: 639-648
36. Busso N, Dudler J, Salvi R, Peclat V, Lenain V, Marcovina S, Darioli R, Nicod P, So AK, Mooser V. Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints. Am J Pathol 2001;159:1445-1453
37. Jaspard B, Fournier N, Vieitez G, Atger V, Barbaras R, Vieu C, Manent J, Chap H, Perret B, Collet X. Structural and functional comparison of HDL from homologous human plasma and follicular fluid. A model for extravascular fluid. Arterioscler Thromb Vasc Biol 1997;17:1605-1613
38. Bloom MS, Kim K, Fujimoto VY, Browne RW. Variability in the components of highdensity lipoprotein particles measured in human ovarian follicular fluid: A crosssectional analysis. Fertil Steril 2014;101:1431-1440
39. Krstic RV. Human Microscopic Anatomy. Berlin: Springer-Verlag; 1994
40. von Eckardstein A, Huang Y, Kastelein JJ, Geisel J, Real JT, Kuivenhoven JA, Miccoli R, Noseda G, Assmann G. Lipid-free apolipoprotein (apo) A-I is converted into alphamigrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients. Atherosclerosis 1998;138:25-34
41. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203
42. Lee M, Sommerhoff CP, von EA, Zettl F, Fritz H, Kovanen PT. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol 2002;22:2086-2091
43. Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 2006;1761:655-666
44. Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E, Martinez LO. Ecto-F1-ATPase: A moonlighting protein complex and an unexpected apoA-I receptor. World J Gastroenterol 2010;16:5925-5935
45. Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The b-chain of cell surface F0F1 ATPase modulates ApoA-I andHDLtranscytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 2012;32:131-139
46. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of highdensity lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010;30:1642-1648
47. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, Yamamura K. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: Special reference to expression of glucose transporter isoforms. Endocrinology 1990; 127:126-132
48. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-122
49. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, Grant S, Hanahan D, Baekkeskov S. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA 1988;85:9037-9041
50. Chick WL,Warren S, Chute RN, Like AA, Lauris V, Kitchen KC. A transplantable insulinoma in the rat. Proc Natl Acad Sci USA 1977;74:628-632
51. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992;130:167-178
52. Puyal J, Petremand J, Dubuis G, Rummel C, Widmann C. HDLs protect the MIN6 insulinoma cell line against tunicamycin-induced apoptosis without inhibiting ER stress and without restoring ER functionality. Mol Cell Endocrinol 2013;381:291-301
53. Petremand J, Puyal J, Chatton JY, Duprez J, Allagnat F, Frias M, James RW,Waeber G, Jonas JC, Widmann C.HDLs protect pancreatic beta-cells against ER stress by restoring protein folding and trafficking. Diabetes 2012;61:1100-1111
54. Petremand J, Bulat N, ButtyAC, Poussin C, Rutti S,AuK, Ghosh S,MooserV, Thorens B, Yang J-Y, Widmann C,Waeber G. Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta cells. Mol Endocrinol 2009;23:1572-1586
55. Abderrahmani A, NiederhauserG, Favre D, Abdelli S, Ferdaoussi M, Yang J-Y, Regazzi R, WidmannC,Waeber G.Humanhigh-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007;50:1304-1314
56. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G. Insulin-secreting b-cell dysfunction induced by human lipoproteins. J Biol Chem 2003;278:18368-18375
57. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, MeierDT, Niclauss N, Berney T, Donath MY, von Eckardstein A. Low and high-density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells. Endocrinology 2009;150:4521-4530
58. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002;143:3449-3453
59. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 2002;7:335-345
60. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008;29:42-61
61. Volchuk A, Ron D. The endoplasmic reticulum stress response in the pancreatic betacell. Diabetes Obes Metab 2010;12 (Suppl. 2):48-57
62. Li XA, Titlow WB, Jackson BA, Giltiay N, Nikolova-Karakashian M, Uittenbogaard A, Smart EJ. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem 2002;277:11058-11063
63. Oeckinghaus A, Ghosh S. The NF-kB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009;1:a000034
64. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-242
65. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kB is the answer- role of Rel/NF-kB in the regulation of apoptosis. Oncogene 2003;22:8961-8982
66. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic b-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 2005;54 Suppl 2:S97-S107
67. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, ReineckeM. Mechanisms of b-cell death in type 2 diabetes. Diabetes 2005;54 Suppl 2:S108-S113
68. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: From concept to clinical translation. Endocr Rev 2008;29:334-350
69. Ortis F, Pirot P, Naamane N, KreinsAY, Rasschaert J, Moore F, Theatre E, Verhaeghe C, Magnusson NE, Chariot A, Orntoft TF, Eizirik DL. Induction of nuclear factor kB and its downstream genes by TNFa and IL-1b has a pro-Apoptotic role in pancreatic beta cells. Diabetologia 2008;51:1213-1225
70. Bulat N, Jaccard E, Peltzer N, Khalil H, Yang J-Y, Dubuis G, Widmann C. RasGAPderived fragment N increases the resistance of beta cells towards apoptosis in NOD mice and delays the progression from mild to overt diabetes. PLoS ONE 2011;6:e22609
71. Hammar EB, Irminger JC, Rickenbach K, Parnaud G, Ribaux P, Bosco D, Rouiller DG, Halban PA. Activation of NF-kB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. J Biol Chem 2005;280: 30630-30637
72. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CREdependent pathway: Effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004;24:871-877
73. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal 2011;23: 1515-1527
74. Khalil H, Bertrand MJ, Vandenabeele P, Widmann C. Caspase-3 and RasGAP: A stresssensing survival/demise switch. Trends Cell Biol 2013;24:83-89
75. Yang J-Y, Widmann C. The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NFkB activation. J Biol Chem 2002;277:14641-14646
76. Yang J-Y,Walicki J, Abderrahmani A, Cornu M,Waeber G, Thorens B, Widmann C. Expression of an uncleavable N-terminal RasGAP fragment in insulin-secreting cells increases their resistance toward apoptotic stimuli without affecting their glucose-induced insulin secretion. J Biol Chem 2005;280:32835-32842
77. Yang J-Y,Walicki J, Jaccard E, Dubuis G, Bulat N, Hornung JP, Thorens B, Widmann C. Expression of the NH2-terminal fragment of RasGAP in pancreatic b-cells increases their resistance to stresses and protects mice from diabetes. Diabetes 2009;58: 2596-2606
78. Daval M, Gurlo T, Costes S, Huang CJ, Butler PC. Cyclin-dependent kinase 5 promotes pancreatic beta-cell survival via Fak-Akt signaling pathways. Diabetes 2011;60: 1186-1197
79. Wang X, Liu Y, Yang Z, Zhang Z, ZhouW, Ye Z, ZhangW, Zhang S, Yang Z, Feng X, Chen F, Hu R. Glucose metabolism-related protein 1 (GMRP1) regulates pancreatic beta cell proliferation and apoptosis via activation of Akt signalling pathway in rats and mice. Diabetologia 2011;54:852-863
80. Shuai H, Zhang J, Zhang J, Xie J, Zhang M, Yu Y, Zhang L. Erythropoietin protects pancreatic beta-cell line NIT-1 cells against cytokine-induced apoptosis via phosphatidylinositol 3-kinase/Akt signaling. Endocr Res 2011;36:25-34
81. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010; 285:33623-33631
82. Widenmaier SB, Ao Z, Kim SJ,Warnock G, McIntosh CH. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the b-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009;284:30372-30382
83. Yano T, Liu Z, Donovan J, Thomas MK, Habener JF. Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes 2007;56:2946-2957
84. WenteW, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic betacell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006;55:2470-2478
85. Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA. Glucose promotes pancreatic islet b-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol Endocrinol Metab 2002;283:E784-E793
86. Higa M, Shimabukuro M, Shimajiri Y, Takasu N, Shinjyo T, Inaba T. Protein kinase B/Akt signalling is required for palmitate-induced beta-cell lipotoxicity. Diabetes Obes Metab 2006;8:228-233
87. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003;278:9142-9149
88. RenteroC, Evans R,Wood P, Tebar F, Vila dM, Cubells L, De DI, Hayes TE, Hughes WE, Pol A, Rye KA, Enrich C, Grewal T. Inhibition of H-Ras and MAPK is compensated by PKC-dependent pathways in annexin A6 expressing cells. Cell Signal 2006;18: 1006-1016.
89. Zhang Q, Yin H, Liu P, Zhang H, She M. Essential role ofHDLon endothelial progenitor cell proliferation with PI3K/Akt/cyclinD1as the signal pathway. Exp Biol Med (Maywood) 2010;235:1082-1092
90. Schmidt A, Geigenmuller S, VolkerW, Buddecke E. The antiatherogenic and antiinflammatory effect ofHDL-Associated lysosphingolipids operates via Akt -.NF-kappaB signalling pathways in human vascular endothelial cells. Basic Res Cardiol 2006;101: 109-116
91. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-Associated lysosphingolipids. J Biol Chem 2001;276:34480-34485
92. Dupraz P, Rinsch C, PralongWF, Rolland E, Zufferey R, Trono D, Thorens B. Lentivirusmediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther 1999;6:1160-1169
93. Karlsen AE, Heding PE, Frobose H, Ronn SG, Kruhoffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N. Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1b-mediated toxicity through inhibition of multiple nuclear factor-kB-regulated proapoptotic pathways. Diabetologia 2004;47:1998-2011
94. Hetz C. The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012;13:89-102
95. Jager R, Bertrand MJ, Gorman AM, Vandenabeele P, Samali A. The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress. Biol Cell 2012;104:259-270
96. Sambrook JF. The involvement of calcium in transport of secretory proteins from the endoplasmic reticulum. Cell 1990;61:197-199
97. Kharroubi I, Ladriere L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: Role of nuclear factor-kB and endoplasmic reticulum stress. Endocrinology 2004;145: 5087-5096
98. Cardozo AK, Ortis F, Storling J, Feng YM, Rasschaert J, Tonnesen M, Van EF, Mandrup-Poulsen T, Herchuelz A, Eizirik DL. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic b-cells. Diabetes 2005;54:452-461
99. Luciani DS, Gwiazda KS, Yang TL, Kalynyak TB, Bychkivska Y, Frey MH, Jeffrey KD, Sampaio AV, Underhill TM, Johnson JD. Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and beta-cell death. Diabetes 2009;58:422-432
100. Tonnesen MF, Grunnet LG, Friberg J, Cardozo AK, Billestrup N, Eizirik DL, Storling J, Mandrup-Poulsen T. Inhibition of nuclear factor-kB or Bax prevents endoplasmic reticulum stress- but not nitric oxide-mediated apoptosis in INS-1E cells. Endocrinology 2009;150:4094-4103
101. Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res 1996;227:190-196
102. Wallen E, Sellers RG, Peehl DM. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol 2000;164:836-841
103. Varadarajan S, Bampton ET, Smalley JL, Tanaka K, Caves RE, Butterworth M, Wei J, PellecchiaM, Mitcheson J, GantTW, Dinsdale D, Cohen GM. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ 2012;19:1896-1907
104. Moon JL, Kim SY, Shin SW, Park JW. Regulation of brefeldin A-induced ER stress and apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun 2012;417:760-764
105. Lai E, Bikopoulos G, Wheeler MB, Rozakis-Adcock M, Volchuk A. Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2008;294:E540-E550
106. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, De Court, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009;119: 2103-2111
107. Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy-Luthmoodoo M, Sviridov D,Weber CI, Meneses-Lorente G, Maugeais C, Forbes JM, Kingwell BA. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 2013;113:167-175
108. Barter PJ, Rye KA, Tardif JC,WatersDD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid LevelManagement to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555-562
109. Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta 2009;1791:563-572
110. Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 2007;453:735-744
111. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. b-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007;13:340-347
112. Kruit JK, Wijesekara N, Fox JE, Dai XQ, Brunham LR, Searle GJ, Morgan GP, Costin AJ, Tang R, Bhattacharjee A, Johnson JD, Light PE, Marsh BJ, Macdonald PE, Verchere CB, Hayden MR. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes 2011;60:3186-3196
113. Kang MH, Zhang LH, Wijesekara N, De HW, Butland S, Bhattacharjee A, Hayden MR. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol 2013;33:2724-2732
114. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, Verchere CB, Hayden MR. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 2012;61:653-658
115. Sturek JM, Castle JD, Trace AP, Page LC, Castle AM, Evans-Molina C, Parks JS, Mirmira RG, Hedrick CC. An intracellular role forABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J Clin Invest 2010; 120:2575-2589
116. Kruit JK, Wijesekara N,Westwell-Roper C, Vanmierlo T, De HaanW, Bhattacharjee A, Tang R, Wellington CL, LutJohann D, Johnson JD, Brunham LR, Verchere CB, Hayden MR. Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function. Diabetes 2012;61:659-664
117. Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Sandoval JC, Ohama T, Nakagawa-Toyama Y, Matsuura F, Nishida M, Ishigami M, Hirano K, Sakane N, Kumon Y, Suehiro T, Nakamura T, Shimomura I, Yamashita S. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009; 16:292-296
118. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, Hayden MR, Stroes ES. Carriers of loss-of-function mutations in ABCA1display pancreatic beta-cell dysfunction. Diabetes Care 2010;33:869-874
119. Schou J, Tybjaerg-Hansen A, Moller HJ, Nordestgaard BG, Frikke-Schmidt R. ABC transporter genes and risk of type 2 diabetes: A study of 40,000 individuals from the general population. Diabetes Care 2012;35:2600-2606
120. Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes:Areview of proposedmechanisms. Metabolism 2014;63:735-745